BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  UPDATED: Spruce’s Drug Candidate Reduces Elevated Hormones in Classic CAH Patients

  Spruce Biosciences shared results from two Phase II studies assessing tildacerfont, a non-steroidal, oral antagonist for the treatment of adult patients with classic CAH.

  June 22, 2021

   · 

  4 min read

   · 

  Alex Keown
• 

  FDA

  Pear Picks SPAC Merger to Grow Prescription Digital Therapeutics Platform

  By merging with New Haven’s SPAC Thimble Point Acquisition Corp., Pear will be valued at $1.6 billion.

  June 22, 2021

   · 

  3 min read

   · 

  Kate Goodwin
• 

  Business

  Hong Kong Biotech Scores $255 Million to Take First AI-Discovered Candidate to Clinic

  Founded in 2014, Insilico focuses on using artificial intelligence for drug discovery and development.

  June 22, 2021

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  COVID-19 News: New COVID-19 Vaccine Efficacy, MIS-C and More

  Please check out the biopharma industry’s COVID-19 stories that are trending for June 22, 2021.

  June 22, 2021

   · 

  7 min read

   · 

  BioSpace Editorial Staff
• 

  Drug Development

  COVID-19 Might Have Long-Term Effects on Sense of Taste and Smell, According to UK Researchers

  Recent research shows those who had been hospitalized due to COVID-19 might already have a reduced sense of smell and taste, not just for the short term, but possibly for life.

  June 22, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Cantex Intends to Repurpose Failed Alzheimer’s Drug for Cancer Indications

  Cantex forges a licensing deal with vTv Therapeutics and intends to evaluate the vTv drug as a potential treatment for several cancer-related issues.

  June 22, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  SAB Biotherapeutics Combines With Blank Check Company to List on Nasdaq

  The business combination agreement will advance SAB’s proprietary platform to develop antibody therapies for immune system disorders and other diseases.

  June 22, 2021

   · 

  2 min read

   · 

  Brandon May
• 

  Drug Development

  Roche Presents Positive Clinical Data for Neurology Programs at EAN Annual Meeting

  Roche presented results from several Phase II and III trials at the 7th Congress of the European Academy of Neurology (EAN) Annual Meeting held virtually June 19-22.

  June 22, 2021

   · 

  5 min read

   · 

  Gail Dutton
• 

  Business

  ViiV Signs Licensing Deal for Halozyme’s Tech to Create Long-Acting HIV Drugs

  Halozyme revealed that ViiV will pay $40 million upfront for the exclusive license to four small and large molecule targets and then pay the remaining $175 million in milestones.

  June 22, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Cuba’s COVID-19 Vaccine is 92% Effective, Late-Stage Trials Show

  Cuba’s Abdala vaccine is 92% effective against the novel coronavirus, according to a recent analysis of late-stage trials.

  June 22, 2021

   · 

  2 min read

   · 

  Brandon May